Gravity Diagnostics
State-of-the-art laboratory providing comprehensive diagnostic testing services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | $5.0m | Late VC | |
| Total Funding | 000k | ||
Related Content
Gravity Diagnostics is a CAP-accredited and CLIA-certified laboratory that provides diagnostic testing services across all 50 states. The company was founded in June 2016 by CEO Tony Remington and COO Julie Brazil. Remington, a healthcare industry leader with over two decades of experience, and Brazil, a former registered nurse, acquired the assets of a company called Molecular Diagnostics to gain control over their product and future. Initially, the company struggled, losing nearly $10 million in its first few years.
The COVID-19 pandemic marked a significant turning point. Anticipating the virus's impact, the company pivoted to COVID-19 testing, processing its first sample in March 2020. This led to explosive growth, with revenue increasing from $5 million in 2019 to $87 million by late 2020, and the workforce expanding from around a dozen to nearly 500. Gravity processed its one-millionth COVID-19 sample by October 2020. This rapid expansion was fueled by contracts with state governments, hospitals, universities, and Fortune 500 companies. To manage the demand, the company expanded its lab space by 900%.
The company's business model is centered on providing a wide range of testing services directly to clients, which include healthcare providers, public health organizations, universities, and corporations. Its services include toxicology, pharmacogenetics (PGx), infectious diseases, upper respiratory diseases, and blood testing. A notable product is the GetMyDNA at-home COVID-19 test kit, which received FDA emergency use authorization in March 2021. The business generates revenue by providing these testing services and has moved all payor billing in-house as of January 2021. The company has received investments, including a $5 million financing round in February 2025 from Advantage Capital and the Community Development Venture Capital Alliance to support facility enhancements and new product development.
Keywords: diagnostic laboratory, CLIA-certified lab, CAP-accredited, toxicology testing, pharmacogenetics, COVID-19 testing, infectious disease diagnostics, blood testing, laboratory services, healthcare technology, at-home testing, PCR testing, consumer-initiated testing, molecular diagnostics, medical laboratory, public health testing, corporate wellness testing, diagnostic solutions, lab testing provider, GetMyDNA